Becker's Healthcare July 10, 2024
The drug class that includes Ozempic, Wegovy and other obesity care treatments has grown in popularity over the last year, affecting several ASC specialties.
Here is how glucagon-like peptide 1 receptor agonists — some of which have been approved by the FDA for weight loss, and others of which are prescribed for that purpose off-label — could impact five specialties:
Orthopedics: As orthopedic surgeons see more patients taking GLP-1s, many agree that more research is needed into how they could affect procedures moving forward. In addition, two studies presented in February examined the impact that semaglutide, which is sold as Ozempic to treat Type 2 diabetes and as Wegovy for weight loss, could have on patients undergoing total...
Today's Sponsors
Today's Sponsor